Share your feedback in a quick live call and enjoy 6 months of Gainer Pro FREE!🎉 Got 10 minutes? Join a quick live call, share your feedback, and get 6 months of Gainer Pro FREE! 🚀 Only 25 spots - book now!
Share your feedback in a quick live call and enjoy 6 months of Gainer Pro FREE!🎉 Got 10 minutes? Join a quick live call, share your feedback, and get 6 months of Gainer Pro FREE! 🚀 Only 25 spots - book now!
Find the Perfect Plan for Your Investment Journey
N
Latest price
-
52 Week Range
DKK500.20 - DKK1.03K
Next Earnings Date
May 07 2025 (Estimate)
Next Earnings Date
May 07 2025 (Est.)
Latest price
-
Market Cap | DKK2.44T |
EV | DKK2.52T |
Shares Outstanding | 4.44B |
Beta | 0.17 |
Analyst Rating | OUTPERFORM |
Analyst Target Price | DKK801.13 |
P/E 2025E | 19.95x |
P/Revenue 2025E | 6.89x |
Revenue | 27.30% |
EPS | 29.70% |
Operating Cash Flow | 30.10% |
Free Cash Flow | 36.00% |
Revenue | 16.50% |
EPS | 19.20% |
Operating Cash Flow | 15.70% |
Free Cash Flow | 23.80% |
Gross Margin 2025E | 83.85% |
Net Profit Margin 2025E | 34.62% |
ROE 2025E | 70.58% |
ROCE 2024 | 80.78% |
DPS 2025E | DKK13.51 |
Payout Ratio 2025E | 49.02% |
Div. Yield 2025E | 2.46% |
DPS Last 3Y CAGR | 29.90% |
N
Novo Nordisk A/S
NOVO B
Sector
Healthcare
Industry
Biotechnology
CEO
Jorgensen, Lars
Employees
76,826
Website
www.novonordisk.comIPO Date
2001-01-06
Headquarters
Novo Alle 1, Bagsvaerd, Capital Region of Denmark, 2880, Denmark
NEWSLETTER
© Copyright 2024, All Rights Reserved